Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTerpath-009 adjuvant pembrolizumab with or without V940 in resected NSCLC without pCR after neoadjuvant pembrolizumab plus chemotherapy
jRCT2061240105Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + V940 with Pembrolizumab + placebo (2 arms). Primary endpoint: Disease-Free Survival. Started Apr 2025; status: recruiting.
02
Drugs
pembrolizumabintismeran autogene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061240105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240105.